Invest now
Caplin Point Laboratories share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹2,810.25(-1.14%)September 4, 2026 15:50:04 PM IST
- NSE
- BSE
- Vol : 223.19 K (NSE + BSE)Last 20 day avg : 273.87 K
Caplin Point Laboratories is trading -1.14% lower at Rs 2,810.25 as compared to its last closing price. Caplin Point Laboratories has been trading in the price range of 2,867.10 & 2,759.05. Caplin Point Laboratories has given 54.78% in this year & 11.98% in the last 5 days. Caplin Point Laboratories has TTM P/E ratio 30.00 as compared to the sector P/E of 37.27.There are 2 analysts who have initiated coverage on Caplin Point Laboratories. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 176.91 Crores in its last quarter.Listed peers of Caplin Point Laboratories include Sun Pharmaceutical Industries (-0.26%), Divi's Laboratories (-1.57%), Torrent Pharmaceuticals (-0.99%).The Mutual Fund holding in Caplin Point Laboratories was at 2.03% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Caplin Point Laboratories was at 5.76% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 06 Sep 2026, 09:09 AM IST
- BetaMedium volatility1.07Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.28Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.03The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values32.60Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.66The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Caplin Point Laboratories News
Caplin Point Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,899.00 | -0.26 | 4,55,622.97 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,100.00 | -1.57 | 2,41,576.41 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,857.00 | -0.99 | 1,84,738.06 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,385.00 | -0.29 | 1,11,888.39 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,121.00 | -1.23 | 1,11,820.17 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allCaplin Point Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-12 | Quarterly Results & Final Dividend |
| 2026-05-14 | Audited Results & Interim Dividend |
| 2026-02-05 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
About the company Caplin Point Laboratories
- IndustryBiotechnology & Drugs
- ISININE475E01026
- BSE Code524742
- NSE CodeCAPLIPOINT
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Caplin Point Laboratories Share Price FAQs
Caplin Point Laboratories is trading at 2810.25 as on Fri Sep 04 2026 10:20:04. This is -1.14% lower as compared to its previous closing price of 2842.80.
The market capitalization of Caplin Point Laboratories is 21361.18 Cr as on Fri Sep 04 2026 10:20:04.
The average broker rating on Caplin Point Laboratories is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Caplin Point Laboratories is 2874.00 whereas the 52 wk low is 1502.45
Caplin Point Laboratories can be analyzed on the following key metrics -
- TTM P/E: 30.00
- Sector P/E: 37.27
- Dividend Yield: 0.28%
- D/E ratio: -
Caplin Point Laboratories reported a net profit of 641.24 Cr in 2026.
The Mutual Fund Shareholding was 2.03% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Caplin Point Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.